IP Library Granted Patent US 10,195,159
Granted Patent B2
US 10,195,159 · App. 14/674,098 · Granted Feb 5, 2019

Processes and apparatus for extraction of active substances and enriched extracts from natural products

Inventors: Brian Anthony Whittle (Hornsea, GB); Geoffrey Guy (Glansvilles Wooton, GB); David Victor Downs (Canterbury, GB); David W. Pate (Amsterdam, NL)
Assignee: GW Pharma Limited
A61K31/05A61K31/352A61K36/185B01D11/028B01D11/0242B01D11/0273B01D11/0288B01D2011/007
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,195,159
App. No.
14/674,098
Granted
Feb 5, 2019
Kind
B2
Abstract

Processes for preparing extracts of natural products such as plant material, and for preparing purified extracts from crude extracts of natural products, by extraction with hot gas. Apparatus suitable for use in preparing extracts of natural products are also described.

Claims (9)

1. A cannabinoid-rich extract which is substantially free of volatile terpenes and ballast, and has a high content of cannabidiol (CBD) and only trace amounts of tetrahydrocannabinolic acid (THCA) and cannabidiolic acid (CBDA), and wherein the majority of the cannabinoids are present in the decarboxylated neutral form.

2. The cannabinoid-rich extract as claimed in claim 1 , wherein said extract has a profile by gas chromatographic analysis that comprises peaks as defined by retention times in one of the following sets of peaks:

(1) 35.7±1 minute (CBD);

(2) 24.1±1 minute, 35.9±1 minute (CBD), and 49.7±1 minute;

(3) 32.1±1 minute, 35.7±1 minute (CBD), and 43.5±1 minute; or

(4) 35.7±1 minute (CBD), and 45.8±1 minute.

3. The cannabinoid-rich extract as claimed in claim 1 , wherein said extract has a profile by gas chromatographic analysis that comprises peaks as defined by the following retention times: 32.1±1 minute, 35.7±1 minute (CBD), and 43.5±1 minute.

4. The cannabinoid-rich extract as claimed in claim 1 , wherein said extract comprises about 98% (w/w) cannabidiol (CBD), 1.5% (w/w) tetrahydrocannabinol (THC), 0.5% (w/w) cannabinol (CBN) and only trace amounts of ballast.

5. The cannabinoid-rich extract as claimed in claim 1 , wherein said extract is substantially free of tetrahydrocannabinol (THC).

Assignments (2)
SECURITY AGREEMENT Recorded Jul 22, 2021
From: GW PHARMA LIMITED; GW RESEARCH LIMITED
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 056958/0493 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2015
From: WHITTLE, BRIAN; GUY, GEOFFREY; DOWNS, DAVID; PATE, DAVID W.
To: GW PHARMA LIMITED
Reel/Frame 035802/0698 →
Priority Claims (1)
GB 0111046.9 · May 4, 2001 · national
Continuity (3)
Continuation 12618347 · Nov 13, 2009
Continuation 10476718
Related Publication 20160038437A1 · Feb 11, 2016
Cited By (10)
US 12,186,280 US 12,268,699 US 12,297,181 US 12,318,479 US 12,409,131 US 12,409,132 US 12,420,214 US 12,544,390 US 12,582,663 US 12,606,535